{"id":2154,"date":"2021-11-01T00:00:00","date_gmt":"2021-11-01T00:00:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3558306_CN58306_0"},"modified":"2021-11-01T00:00:00","modified_gmt":"2021-11-01T00:00:00","slug":"hopstem-completed-40-million-usd-series-b-financing-to-develop-safe-effective-and-affordable-ipsc-cell-therapies-for-global-patients","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=2154","title":{"rendered":"HOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients"},"content":{"rendered":"<p><span class=\"xn-location\">CAYMAN ISLANDS<\/span>, British Overseas Territory, <span class=\"xn-chron\">Oct. 31, 2021<\/span> \/PRNewswire\/ &#8212; After A++ financing in May this year, HOPSTEM announced that the company has completed a round of near <span class=\"xn-money\">40 million USD<\/span> Series B financing, led by a top VC\/PE in biomedical field, followed by Lilly Asia Ventures and current shareholder YuanBio Venture Capital.<\/p>\n<p>According to the company, this round of financing will be used to support the IND application of hNPC01 (with stroke as the first indication) both in <span class=\"xn-location\">China<\/span> and <span class=\"xn-location\">the United States<\/span>, the following clinical trial, expansion of product pipelines, and development of automated closed-system manufactory processes.<\/p>\n<p>HOPSTEM is an innovative startup company aiming to develop safe, effective and affordable iPSC cell therapy products for global patients. HOPSTEM owns 40,000 square feet GMP facility and R&amp;D center, with CMC platform and quality system for iPSC cell products in <span class=\"xn-location\">China<\/span> following EMA and US GMP and regulations. The GMP iPSC line and cell bank are established for global cell product development and out-licensing. Core patents of HOPSTEM have been authorized in <span class=\"xn-location\">China<\/span> and entered <span class=\"xn-location\">the United States<\/span>, the European Union, and <span class=\"xn-location\">Japan<\/span> through PCT, with more patents and products being deployed.<\/p>\n<p id=\"PURL\"><img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN58306&amp;sd=2021-10-31\"> View original content:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/hopstem-completed-40-million-usd-series-b-financing-to-develop-safe-effective-and-affordable-ipsc-cell-therapies-for-global-patients-301412466.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/hopstem-completed-40-million-usd-series-b-financing-to-develop-safe-effective-and-affordable-ipsc-cell-therapies-for-global-patients-301412466.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CAYMAN ISLANDS, British Overseas Territory, Oct. 31, 2021 \/PRNewswire\/ &#8212; After A++ financing in May this year, HOPSTEM announced that the company has completed a round of near 40 million USD Series B financing, led by a top VC\/PE in biomedical field, followed by Lilly Asia Ventures and current shareholder YuanBio Venture Capital. According to [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":2155,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-2154","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=2154\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients - My Blog\" \/>\n<meta property=\"og:description\" content=\"CAYMAN ISLANDS, British Overseas Territory, Oct. 31, 2021 \/PRNewswire\/ &#8212; After A++ financing in May this year, HOPSTEM announced that the company has completed a round of near 40 million USD Series B financing, led by a top VC\/PE in biomedical field, followed by Lilly Asia Ventures and current shareholder YuanBio Venture Capital. According to [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=2154\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-01T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/11\/hopstem-completed-40-million-usd-series-b-financing-to-develop-safe-effective-and-affordable-ipsc-cell-therapies-for-global-patients.png\" \/>\n\t<meta property=\"og:image:width\" content=\"16\" \/>\n\t<meta property=\"og:image:height\" content=\"16\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=2154#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=2154\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"HOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients\",\"datePublished\":\"2021-11-01T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=2154\"},\"wordCount\":221,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=2154#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/hopstem-completed-40-million-usd-series-b-financing-to-develop-safe-effective-and-affordable-ipsc-cell-therapies-for-global-patients.png\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=2154\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=2154\",\"name\":\"HOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=2154#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=2154#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/hopstem-completed-40-million-usd-series-b-financing-to-develop-safe-effective-and-affordable-ipsc-cell-therapies-for-global-patients.png\",\"datePublished\":\"2021-11-01T00:00:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=2154#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=2154\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=2154#primaryimage\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/hopstem-completed-40-million-usd-series-b-financing-to-develop-safe-effective-and-affordable-ipsc-cell-therapies-for-global-patients.png\",\"contentUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/hopstem-completed-40-million-usd-series-b-financing-to-develop-safe-effective-and-affordable-ipsc-cell-therapies-for-global-patients.png\",\"width\":16,\"height\":16},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=2154#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=2154","og_locale":"en_US","og_type":"article","og_title":"HOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients - My Blog","og_description":"CAYMAN ISLANDS, British Overseas Territory, Oct. 31, 2021 \/PRNewswire\/ &#8212; After A++ financing in May this year, HOPSTEM announced that the company has completed a round of near 40 million USD Series B financing, led by a top VC\/PE in biomedical field, followed by Lilly Asia Ventures and current shareholder YuanBio Venture Capital. According to [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=2154","og_site_name":"My Blog","article_published_time":"2021-11-01T00:00:00+00:00","og_image":[{"width":16,"height":16,"url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/11\/hopstem-completed-40-million-usd-series-b-financing-to-develop-safe-effective-and-affordable-ipsc-cell-therapies-for-global-patients.png","type":"image\/png"}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=2154#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=2154"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"HOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients","datePublished":"2021-11-01T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=2154"},"wordCount":221,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=2154#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/11\/hopstem-completed-40-million-usd-series-b-financing-to-develop-safe-effective-and-affordable-ipsc-cell-therapies-for-global-patients.png","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=2154","url":"https:\/\/transmediavictoria.net.au\/?p=2154","name":"HOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=2154#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=2154#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/11\/hopstem-completed-40-million-usd-series-b-financing-to-develop-safe-effective-and-affordable-ipsc-cell-therapies-for-global-patients.png","datePublished":"2021-11-01T00:00:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=2154#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=2154"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=2154#primaryimage","url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/11\/hopstem-completed-40-million-usd-series-b-financing-to-develop-safe-effective-and-affordable-ipsc-cell-therapies-for-global-patients.png","contentUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/11\/hopstem-completed-40-million-usd-series-b-financing-to-develop-safe-effective-and-affordable-ipsc-cell-therapies-for-global-patients.png","width":16,"height":16},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=2154#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"HOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/2154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2154"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/2154\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/media\/2155"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}